Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old, voluntary consent and signed written informed consent~* ECOG 0\~2~* Pathologically diagnosed HER2-negative breast cancer patients with radiologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) breast cancer; HR-positive patients were permitted~* At least one measurable disease lesion before treatment~* Never receive Eribulin Mesylate treatment or anti-angiogenetic therapies before recruitment~* Anticipated survival time is longer than three months~* Brain metastases with stable disease or without clinical symptom~* Blood routine test, liver and kidney function test meet the following criteria: PLT \> 100g / L, Hb \> 9g / L, Neutrophil \> 2.0 g/L; AST and ALT \< 2.5 upper limit of normal (ULN); Cr \< 1.0 ULN; TBIL \< 1.5ULN~* Previously treated with anthracycline-based and taxane-based chemotherapy regimens (at least one line of chemotherapy in the metastatic setting or the recurrence time is less than 1 year from the end of adjuvant or neoadjuvant chemotherapy); for HR-positive/HER2-negative patients, progressed after at least one line of endocrine therapy~* For women with fertility, the pregnancy test before administration was negative, and agreed to take appropriate measures to avoid pregnancy during the study treatment and at least half a year after the end of treatment; Men agreed to take appropriate contraceptive measures during the study treatment and at least half a year after the end of the treatment.~Exclusion Criteria:~* Pregnant or lactating women~* Active infection requiring systemic treatment~* HIV positive~* Suffering from or suspected of suffering from central neuromuscular system diseases~* Serious heart disease; uncontrollable hypertension; history of heavy hemorrhea；recent operation within three months~* The investigator considered that the patient was not suitable for in this study, with any other situation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Eribulin mesylate (Type: PLACEBO_COMPARATOR): Metastatic breast cancer patients receive eribulin mesylate injection alone. The dosage is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle. Patients receive Eribulin untill progression.~Patients were observed for at least 6 months but no longer than 18 months.
- Eribulin mesylate combined with Anlotinib (Type: EXPERIMENTAL): Metastatic breast cancer patients receive Eribulin mesylate combined with Anlotinib. The dosage of Eribulin mesylate is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle.~Anlotinib dosage is 12mg per day for consecutive 14 days (21 days per cycle). Patients receive Anlotinib untill progression.~Patients were observed for at least 6 months but no longer than 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).